PayPal vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Jose digital payments platform (NASDAQ: PYPL) at $31.8B 2024 revenue processing $1.68T volume across 434M accounts; CEO Chriss AI personalization strategy with Fastlane checkout competing with Stripe and Apple Pay for digital commerce.
About
PayPal Holdings is a San Jose, California-based digital payments technology platform — publicly traded on NASDAQ (NASDAQ: PYPL) at approximately $70 billion market capitalization — providing 434 million active accounts across 200+ markets with digital wallet services (PayPal consumer, Venmo P2P payments), merchant payment processing (PayPal Checkout, Braintree enterprise processing), and buy now pay later (Pay Later). In 2024, PayPal processed $1.68 trillion in total payment volume across 26.3 billion transactions, reporting $31.8 billion in revenue (7% year-over-year growth) and $6.8 billion in free cash flow — with the board authorizing a new $15 billion share repurchase program. Under CEO Alex Chriss (since September 2023), PayPal launched Fastlane (accelerated guest checkout), AI-powered merchant personalization, and PayPal Everywhere (debit card rewards) as new revenue initiatives. Founded in 1998 (as Confinity), spinoff from eBay in 2015.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.